These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15136934)

  • 21. Interferon: the quintessence of a quinquagenarian.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2009; 71(1-2):5-14. PubMed ID: 19739395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: more questions than answers.
    Su TH; Kao JH; Chen DS
    Hepatology; 2007 Jun; 45(6):1586-7; author reply 1587-8. PubMed ID: 17538939
    [No Abstract]   [Full Text] [Related]  

  • 23. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the evidence from clinical trials in chronic hepatitis C.
    Brown RS
    J Viral Hepat; 2006 May; 13 Suppl 1():15-25. PubMed ID: 16630043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver function under interferon/ribavirin therapy of chronic hepatitis C.
    Stintzing S; Schmitt C; Ocker M; Ganslmayer M; Zopf S; Gahr S; Hahn EG; Herold C
    Hepatogastroenterology; 2009; 56(90):462-5. PubMed ID: 19579621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New developments in the therapy of ocular herpes simplex.
    Pavan-Langston D
    Int Ophthalmol Clin; 1973; 13(4):53-63. PubMed ID: 4784004
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic hepatitis C with repeatedly normal transaminase levels].
    Dhumeaux D; Hézode C
    Rom J Gastroenterol; 2002 Jun; 11(2):129-33. PubMed ID: 12145669
    [No Abstract]   [Full Text] [Related]  

  • 29. Severe toxicity of fialuridine (FIAU).
    Bari A
    N Engl J Med; 1996 Apr; 334(17):1135; author reply 1137-8. PubMed ID: 8598879
    [No Abstract]   [Full Text] [Related]  

  • 30. Genetic factors predicting response to interferon treatment for viral hepatitis C.
    Stärkel P
    Gut; 2008 Apr; 57(4):440-2. PubMed ID: 18334658
    [No Abstract]   [Full Text] [Related]  

  • 31. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
    P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C: current and future therapies.
    Mishra P; Jensen DM
    Mt Sinai J Med; 2008 Aug; 75(4):405-14. PubMed ID: 18729159
    [No Abstract]   [Full Text] [Related]  

  • 33. Future treatment of chronic hepatitis C.
    Keeffe EB
    Antivir Ther; 2007; 12(7):1015-25. PubMed ID: 18018759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis].
    Friedrich-Rust M; Forestier N; Zeuzem S
    Dtsch Med Wochenschr; 2005 Dec; 130 Suppl 5():S229-30. PubMed ID: 16435720
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of hepatitis B].
    Telegdy L
    Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical use of interferon in hepatitis B and C.
    Schalm SW
    Verh K Acad Geneeskd Belg; 2009; 71(1-2):87-99. PubMed ID: 19739400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C, depressive symptoms, viral load, and therapy: interactions and reactions.
    Douglas SD
    Brain Behav Immun; 2005 Jan; 19(1):20-2. PubMed ID: 15581734
    [No Abstract]   [Full Text] [Related]  

  • 38. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of host insulin resistance on fibrosis and response to interferon in chronic hepatitis C.
    Moţa M; Popa S; Mota E; Diaconescu I; Gheorghiţoiu I; Panduru M
    Rom J Intern Med; 2008; 46(2):105-12. PubMed ID: 19284081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Pellicano R; Puglisi G; Ciancio A; Balzola F; Saracco G; Ciccone G; Baldi I; Abate ML; Smedile A; Rizzetto M
    J Med Virol; 2008 Apr; 80(4):628-31. PubMed ID: 18297716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.